 <h1>Entacapone Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of entacapone include:</b> urine discoloration.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to entacapone: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, entacapone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking entacapone:</p><p>
<i>More common</i>
</p><ul>
<li>Absence of or decrease in body movements</li>
<li>hyperactivity</li>
<li>increase in body movements</li>
<li>seeing, hearing, or feeling things that are not there</li>
<li>twisting</li>
<li>twitching</li>
<li>uncontrolled repetitive movements of the tongue, lips, face, arms, or legs</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Cough or hoarseness</li>
<li>fever or chills</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Confusion</li>
<li>muscle cramps</li>
<li>pain</li>
<li>shortness of breath</li>
<li>stiffness</li>
<li>unusual tiredness or weakness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of entacapone may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>constipation</li>
<li>diarrhea</li>
<li>dizziness</li>
<li>nausea</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>anxiety</li>
<li>belching</li>
<li>bruising</li>
<li>burning feeling in the chest or stomach</li>
<li>difficult or labored breathing</li>
<li>dry mouth</li>
<li>heartburn</li>
<li>indigestion</li>
<li>irritability</li>
<li>loss of strength or energy</li>
<li>muscle pain or weakness</li>
<li>passing gas</li>
<li>restlessness</li>
<li>sleepiness or unusual drowsiness</li>
<li>small, red spots on the skin</li>
<li>stomach discomfort, upset, or tenderness</li>
<li>sweating increased</li>
<li>tightness in the chest</li>
<li>tremor</li>
<li>trouble sleeping</li>
<li>unusual or unpleasant (after) taste</li>
<li>unusual weak feeling</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to entacapone: oral tablet</i></p><h3>Nervous system</h3><p>There were no cases of neuroleptic malignant syndrome during clinical trials.  Since market introduction, there have been isolated cases, especially following abrupt reduction or discontinuation of this drug and other concomitant dopaminergic drugs.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Dyskinesia (up to 27%), hyperkinesia (10%)</p>
<p><b>Common</b> (1% to 10%): Hypokinesia, dizziness, somnolence, taste perversion, aggravated parkinsonism, dystonia, headache, tremor</p>
<p><b>Frequency not reported</b>: Falling asleep during activities of daily living</p>
<p><b>Postmarketing reports</b>: Neuroleptic malignant syndrome<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 14%), diarrhea (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, constipation, vomiting, dry mouth, dyspepsia, flatulence, gastritis, gastrointestinal disorders</p>
<p><b>Very rare</b> (less than 0.01%): Anorexia</p>
<p><b>Postmarketing reports</b>: Colitis<sup>[Ref]</sup></p><p>In clinical trials, diarrhea occurred in approximately 10% of patients.  It was generally mild to moderate, but in 1.3% of people it was severe.  Upon discontinuation, diarrhea generally resolved.  There have been postmarketing reports of drug-induced microscopic colitis, primarily lymphocytic colitis.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urine discoloration (10%)<sup>[Ref]</sup></p><h3>General</h3><p>The most commonly reported adverse reactions included dyskinesia, urine discoloration, diarrhea, nausea, hyperkinesia, abdominal pain, vomiting, and dry mouth.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea</p>
<p><b>Frequency not reported</b>: Pulmonary fibrosis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Increased sweating</p>
<p><b>Rare</b> (less than 0.1%): Erythematous, maculopapular rash</p>
<p><b>Very rare</b> (less than 0.01%): Urticaria</p>
<p><b>Frequency not reported</b>: Skin hair, beard, and nail discolorations<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Isolated cases of rhabdomyolysis have occurred in patients treated with this drug.  The complicated nature of these cases makes it difficult to determine the role this drug may have had.  Rhabdomyolysis has been reported secondary to severe dyskinesias or neuroleptic malignant syndrome (NMS) in patients with Parkinson's disease.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Back pain, falls, leg cramps</p>
<p><b>Postmarketing reports</b>: Rhabdomyolysis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, insomnia, hallucinations, confusion, paranoia</p>
<p><b>Uncommon</b> (0.1% to 1%): Agitation</p>
<p><b>Frequency not reported</b>: Impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Purpura, decreased hemoglobin<sup>[Ref]</sup></p><p>A clinically significant decrease in hemoglobin has been observed in 1.8% of patients.  The underlying mechanism may involve decreased absorption of iron from the gastrointestinal tract.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, asthenia, pain, vertigo<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>The incidence of myocardial infarction and other ischemic heart disease events was 0.43% and 1.54%, respectively, in an analysis of 13 double-blind studies involving 2082 patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Ischemic heart disease events other than myocardial infarction (e.g., angina pectoris, postural hypotension</p>
<p><b>Uncommon</b> (0.1% to 1%): Myocardial infarction<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (less than 0.1%): Abnormal liver function tests</p>
<p><b>Postmarketing reports</b>: Hepatitis with mainly cholestatic features<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Comtan (entacapone)" Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about entacapone</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>11 Reviews</li>
<li>Drug class: dopaminergic antiparkinsonism agents</li>
<li>FDA Alerts (2)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Entacapone &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Comtan</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Parkinson's Disease</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to entacapone: oral tablet</i></p><h3>Nervous system</h3><p>There were no cases of neuroleptic malignant syndrome during clinical trials.  Since market introduction, there have been isolated cases, especially following abrupt reduction or discontinuation of this drug and other concomitant dopaminergic drugs.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Dyskinesia (up to 27%), hyperkinesia (10%)</p><p><b>Common</b> (1% to 10%): Hypokinesia, dizziness, somnolence, taste perversion, aggravated parkinsonism, dystonia, headache, tremor</p><p><b>Frequency not reported</b>: Falling asleep during activities of daily living</p><p><b>Postmarketing reports</b>: Neuroleptic malignant syndrome<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 14%), diarrhea (up to 11%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, constipation, vomiting, dry mouth, dyspepsia, flatulence, gastritis, gastrointestinal disorders</p><p><b>Very rare</b> (less than 0.01%): Anorexia</p><p><b>Postmarketing reports</b>: Colitis<sup>[Ref]</sup></p><p>In clinical trials, diarrhea occurred in approximately 10% of patients.  It was generally mild to moderate, but in 1.3% of people it was severe.  Upon discontinuation, diarrhea generally resolved.  There have been postmarketing reports of drug-induced microscopic colitis, primarily lymphocytic colitis.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urine discoloration (10%)<sup>[Ref]</sup></p><h3>General</h3><p>The most commonly reported adverse reactions included dyskinesia, urine discoloration, diarrhea, nausea, hyperkinesia, abdominal pain, vomiting, and dry mouth.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea</p><p><b>Frequency not reported</b>: Pulmonary fibrosis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Increased sweating</p><p><b>Rare</b> (less than 0.1%): Erythematous, maculopapular rash</p><p><b>Very rare</b> (less than 0.01%): Urticaria</p><p><b>Frequency not reported</b>: Skin hair, beard, and nail discolorations<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Isolated cases of rhabdomyolysis have occurred in patients treated with this drug.  The complicated nature of these cases makes it difficult to determine the role this drug may have had.  Rhabdomyolysis has been reported secondary to severe dyskinesias or neuroleptic malignant syndrome (NMS) in patients with Parkinson's disease.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Back pain, falls, leg cramps</p><p><b>Postmarketing reports</b>: Rhabdomyolysis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, insomnia, hallucinations, confusion, paranoia</p><p><b>Uncommon</b> (0.1% to 1%): Agitation</p><p><b>Frequency not reported</b>: Impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Purpura, decreased hemoglobin<sup>[Ref]</sup></p><p>A clinically significant decrease in hemoglobin has been observed in 1.8% of patients.  The underlying mechanism may involve decreased absorption of iron from the gastrointestinal tract.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, asthenia, pain, vertigo<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>The incidence of myocardial infarction and other ischemic heart disease events was 0.43% and 1.54%, respectively, in an analysis of 13 double-blind studies involving 2082 patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Ischemic heart disease events other than myocardial infarction (e.g., angina pectoris, postural hypotension</p><p><b>Uncommon</b> (0.1% to 1%): Myocardial infarction<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (less than 0.1%): Abnormal liver function tests</p><p><b>Postmarketing reports</b>: Hepatitis with mainly cholestatic features<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Comtan (entacapone)" Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2>More about entacapone</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>11 Reviews</li>
<li>Drug class: dopaminergic antiparkinsonism agents</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Entacapone &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Parkinson's Disease</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>